Claims data support tirzepatide cardiovascular effects in diabetes patients
The real-world analysis adds observational evidence alongside the dedicated outcomes trial program for the dual GIP/GLP-1 agonist.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 7 03:00 ETSource: tctmd.com
The wire
- 01TCTMD reports that insurance claims data lend support to cardiovascular benefits of tirzepatide in patients with type 2 diabetes.
- 02Clinicians weighing incretin choice in diabetes patients with cardiovascular risk have another data point, though claims work is not a substitute for randomized outcomes evidence.
- 03Claims analyses carry confounding and channeling bias; details of the cohort, endpoints and effect size should be checked against the published report.
From the source
Read at tctmd.comClaims Data Lend Support to Tirzepatide’s CV Effects in Patients With Diabetes
